Visualizing CAR-T Cell Therapy in Multiple Myeloma Using a BCMA-Targeted PET Probe is a EARLY_PHASE1 clinical asset sponsored by Xuzhou Medical University in Non-invasive CAR-T Cell Monitoring, BCMA-targeted PET Imaging, CAR-T Cell Biodistribution and Persistence, GMP-compliant Radiopharmaceutical Preparation. SEO and diligence focus: BCMA-Targeting CAR-T Cell Therapy, PET/CT Imaging, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.